欧洲黑色素瘤跨学科共识指南:诊断部分(2019更新)
该指南由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和欧洲癌症研究与治疗组织多学科专家共同制定,基于系统文献综述与专家经验,提出皮肤黑色素瘤诊断与随访推荐。诊断需临床结合皮肤镜并病理确认,按AJCC第8版分期,并按分期推荐影像与突变检测。
要点
- 疑似黑色素瘤须皮肤镜检查并由组织病理学确认。
- 厚度≤0.8 mm薄黑色素瘤无需进一步影像检查。
- III期及以上推荐突变检测,尤其BRAF V600。
核心结论
- 皮肤黑色素瘤诊断应临床结合皮肤镜并始终经组织病理学确认,按AJCC第8版分期指导影像与突变检测。
- 分期驱动影像检查与随访,从III期起推荐突变检测尤其BRAF V600。
- 随访频率与检查范围缺乏证据,指南提出基于分期的最低要求随访方案。
研究设计与样本
- 由EDF、EADO和EORTC多学科专家协作制定,基于系统文献综述与专家经验形成推荐。
- 指南有效期至2021年底。
主要发现
- 皮肤黑色素瘤是潜在最危险的皮肤肿瘤,导致90%的皮肤癌死亡。
- 疑似黑色素瘤需组织病理学检查;序贯数字皮肤镜和全身摄影可用于高危人群早期发现。
- 共聚焦反射显微镜在特殊病例中可改善临床诊断。
关键数值与推荐
- 黑色素瘤按AJCC第8版分类。
- 肿瘤厚度≤0.8 mm的薄黑色素瘤不需进一步影像诊断。
- 从IB期起推荐淋巴结超声检查,但不推荐其他影像检查。
- 从IIC期起推荐CT或PET-CT全身检查联合脑MRI。
- 从III期及以上推荐突变检测,尤其BRAF V600突变。
临床怎么用
- 临床疑似黑色素瘤应行皮肤镜检查并取组织病理确诊。
- 按AJCC第8版分期决定影像检查:≤0.8 mm不做进一步影像,IB期起查淋巴结超声,IIC期起全身CT或PET-CT联合脑MRI。
- III期及以上检测BRAF V600等突变以指导治疗。
- 按分期随访以尽早发现复发和第二原发黑色素瘤。
局限性
- 随访检查的频率与范围缺乏证据支持,分期随访方案基于指南组经验,仅覆盖最低要求。
- 指南有效期至2021年底,需关注后续更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.
引用
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. Eur J Cancer. 2020. PMID: 31928887. doi:10.1016/j.ejca.2019.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。